Know Cancer

forgot password

A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1/Phase 2
18 Years
Open (Enrolling)
Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma

Thank you

Trial Information

A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma

The clinical study AT7519M/0004 is an open-label multicenter study to investigate the
efficacy of AT7519M alone and AT7519M in combination with bortezomib in patients with
previously treated multiple myeloma (MM).

Inclusion Criteria:

- Ability to understand the risks of the study and provide signed informed consent

- Age 18 years or older

- Relapsed and or Refractory MM

- Disease progression following at least two systemic treatments for MM

- Patient must be refractory to the last bortezomib

- ECOG performance status 0, 1 or 2

Exclusion Criteria:

- Pregnant or lactating females. Patients of childbearing potential must use
appropriate birth control throughout the study

- Inadequate liver function

- Renal impairment

- Neutrophil count <1.0 x 10^9 /litre in the absence of growth factors

- Platelet count <50 x 10^9 /litre in patients in whom <50% of bone marrow nucleated
cells are plasma cells and <30 x 10^9 /litre in patients in whom ≥50 % of bone marrow
nucleated cells are plasma cells

- Hemoglobin <8g/dl in the absence of transfusion

- Treated corrected calcium >ULN

- Serum creatine phosphokinase >ULN

- All previous cytotoxic therapies for MM must have been completed at least four weeks
prior to treatment with AT7519M (two weeks for all non-cytotoxic therapy)

- Patients may be receiving concomitant therapy with biphosphonates and low dose
corticosteroids. Bisphosphonates doses should be stable for at least 30 days prior to
study drug administration. Corticosteroids doses should be stable for at least 7 days
prior to study treatment

- Prior peripheral stem cell transplant within 12 weeks

- Evidence of mucosal or internal bleeding and/or platelet transfusion refractory
(unable to maintain a platelet count >50 x 10^9 /litre)

- Ongoing infection requiring treatment

- Previous radiotherapy within 2 weeks of the start of the study

- Having previously received treatment with a cyclin-dependent kinase or GSK3beta

- Incomplete recovery from previous radiotherapy other than residual cutaneous effects
or stable < Grade 2 gastrointestinal toxicity

- Prior radiotherapy to the head and neck region for head and neck tumors

- Previous malignancy, except for non-melanomatous skin carcinomas, in situ carcinomas
or malignancies with low risk of recurrence.

- Any severe or uncontrolled systemic conditions (e.g. systemic infection) or current
unstable or uncompensated respiratory or cardiac conditions which makes it
undesirable for the patient to participate in the study or which could jeopardize
compliance with the protocol

- Incomplete recovery from surgery other than stable < Grade 2 toxicity

- Peripheral neuropathy > Grade 2

- Abnormal left ventricular ejection fraction (< lower limit of normal for the
institution for a patient of that age) on echocardiogram

- History of an ischemic cardiac event, including myocardial infarction within 3 months
of study entry

- Congestive cardiac failure of ≥ grade 3 severity according to NYHA functional

- Unstable cardiac disease

- History or presence of bradycardia (≤60bpm), left bundle branch block, heart block,
cardiac pacemaker or significant atrial tachyarrhythmias

- If the patient will receive bortezomib (Velcade) during part C of the study,
concurrent treatment with any medication known strongly to inhibit or induce CYP3A4,
CYP1A2 and CYP2C19 which cannot be discontinued at least two week prior to treatment
with AT7519M (other than corticosteroids)

- Concurrent treatment with any medication that prolongs QT interval and may induce
Torsades de Pointes and which cannot be discontinued at least two weeks prior to
treatment with AT7519M

- Family or personal history of long QTc syndrome or ventricular arrhythmias including
ventricular bigeminy

- Previous history of drug-induced QTc prolongation

- Screening 12-lead ECG with measurable QTc interval according to Fridericia's
Correction of >450 msecs

- Screening 12-lead ECG with ST depression >1 mm in 2 or more leads or T wave inversion
in 2 or more contiguous leads

- Prior history of infection with human immunodeficiency virus (HIV), known active
hepatitis B or C viruses

- Diffuse infiltrative pulmonary or pericardial disease

- Known hypersensitivity to bortezomib, boron or any of the excipients of VelcadeTM

- Epilepsy or other convulsive disorder requiring active management

- Serious psychiatric illness, active alcoholism or drug addiction that may hinder or
confuse follow up evaluation

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaulate the clinical efficacy of AT7519M alone or in combination with bortezomib

Outcome Time Frame:

until patient withdraws

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

November 2010

Completion Date:

October 2013

Related Keywords:

  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Neoplasms
  • Neoplasms, Plasma Cell
  • Neoplasms by Histologic Type
  • Hemostatic Disorders
  • Paraproteinemias
  • Blood Protein Disorders
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Lymphoproliferative Disorders
  • Immunoproliferative Disorders
  • Immune System Diseases
  • Bortezomib
  • Antineoplastic Agents
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Massachusetts General Hospital Boston, Massachusetts  02114-2617
Mt. Sinai Hospital New York, New York  10029
Dana Faber Cancer Institute Boston, Massachusetts  02115
Memorial Sloan-Kettering Cancer Centre New York, New York  10021
MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders Milwaukee, Wisconsin  53226